St. Jude Expands EnSite Precision Launch in EU, Seeks FDA Approval
Tuesday, April 19, 2016
Source: Mass Device
St. Jude Medical (NYSE:STJ) said today it is expanding its commercial release of its EnSite Precision cardiac mapping system in the European Union, and that it is currently pursuing FDA clearance of the system.
The St. Paul, Minn.-based company’s Ensite cardiac mapping system is designed for use in ablation procedures to visualize and aid in catheter navigation in the heart, providing detailed anatomical models and maps. The system is designed to aid in diagnosing arrhythmias, guiding therapy and providing expanded procedural options.
“We developed the EnSite Precision system with insight from world-renowned electrophysiologists to encompass leading mapping capabilities. Providing a best-in-class mapping system combining speed and detail with precision and stability allows physicians to have the information they need to treat both straightforward and complex arrhythmias,” clinical, medical and scientific affairs veep Dr. Srijoy Mahapatra said in a prepared release.
The expanded release includes a new suite of technologies including improved hardware and software features, the company said.